David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

Leukemia

Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).

Lymphoma

Olivier Casasnovas, MD

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version)

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).

Leukemia

Lymphoma

Sagar Lonial, MD, and Alessandra Tedeschi, MD

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).

Leukemia

James Foran, MD

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).

Nov

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Jonathon Cohen, MD, on Deferring MCL Treatment

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version)

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC

Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices

Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression

Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma

A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery